 Lavanya Kondapalli
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 12 | 2024 | 2875 | 1.820 |
Why?
| | Cardiotoxicity | 4 | 2026 | 33 | 1.470 |
Why?
| | Antineoplastic Agents | 5 | 2026 | 2194 | 1.250 |
Why?
| | Cardiovascular Diseases | 9 | 2026 | 2168 | 1.230 |
Why?
| | Myocardial Infarction | 3 | 2023 | 1209 | 0.940 |
Why?
| | Menopause, Premature | 1 | 2025 | 12 | 0.910 |
Why?
| | Genital Neoplasms, Female | 1 | 2026 | 99 | 0.860 |
Why?
| | Carcinoid Heart Disease | 1 | 2022 | 1 | 0.770 |
Why?
| | Echocardiography | 1 | 2026 | 652 | 0.760 |
Why?
| | Breast Neoplasms | 5 | 2026 | 2452 | 0.670 |
Why?
| | Cancer Survivors | 4 | 2024 | 327 | 0.650 |
Why?
| | Myocarditis | 1 | 2021 | 102 | 0.620 |
Why?
| | Pyridazines | 1 | 2020 | 57 | 0.620 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 127 | 0.580 |
Why?
| | Carotid Stenosis | 1 | 2020 | 102 | 0.580 |
Why?
| | Imidazoles | 1 | 2020 | 254 | 0.570 |
Why?
| | Protein Kinase Inhibitors | 2 | 2020 | 969 | 0.540 |
Why?
| | Immunotherapy | 2 | 2023 | 653 | 0.500 |
Why?
| | Atherosclerosis | 1 | 2020 | 409 | 0.500 |
Why?
| | Thrombosis | 1 | 2020 | 393 | 0.470 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 215 | 0.460 |
Why?
| | Anticoagulants | 1 | 2020 | 722 | 0.430 |
Why?
| | Anthracyclines | 5 | 2024 | 47 | 0.390 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 77 | 0.360 |
Why?
| | Stroke | 2 | 2025 | 1256 | 0.360 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1180 | 0.360 |
Why?
| | Fertilization in Vitro | 1 | 2012 | 92 | 0.350 |
Why?
| | Humans | 28 | 2026 | 144759 | 0.290 |
Why?
| | Estradiol | 1 | 2012 | 533 | 0.280 |
Why?
| | Medical Oncology | 2 | 2022 | 332 | 0.280 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2637 | 0.260 |
Why?
| | Cardiac Rehabilitation | 1 | 2026 | 46 | 0.230 |
Why?
| | Echocardiography, Three-Dimensional | 1 | 2026 | 71 | 0.220 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2025 | 40 | 0.220 |
Why?
| | Risk Factors | 7 | 2025 | 10779 | 0.210 |
Why?
| | England | 1 | 2023 | 111 | 0.190 |
Why?
| | Stroke Volume | 1 | 2026 | 651 | 0.190 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2025 | 180 | 0.190 |
Why?
| | Morbidity | 1 | 2022 | 323 | 0.170 |
Why?
| | Exercise Therapy | 1 | 2026 | 473 | 0.170 |
Why?
| | Biology | 1 | 2021 | 91 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 179 | 0.160 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 432 | 0.160 |
Why?
| | Survivors | 1 | 2024 | 520 | 0.160 |
Why?
| | Heart Diseases | 1 | 2023 | 349 | 0.160 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2020 | 69 | 0.160 |
Why?
| | Heart Failure | 2 | 2023 | 2323 | 0.150 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 510 | 0.150 |
Why?
| | Female | 13 | 2026 | 78271 | 0.150 |
Why?
| | Catheter Ablation | 2 | 2014 | 353 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 264 | 0.140 |
Why?
| | Drug Interactions | 1 | 2020 | 398 | 0.140 |
Why?
| | Hypertension | 2 | 2025 | 1263 | 0.140 |
Why?
| | Mental Health | 1 | 2025 | 790 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2020 | 255 | 0.140 |
Why?
| | Taxoids | 3 | 2023 | 116 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2005 | 847 | 0.140 |
Why?
| | Cardiology | 1 | 2020 | 353 | 0.130 |
Why?
| | Atrial Fibrillation | 2 | 2014 | 550 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2023 | 421 | 0.130 |
Why?
| | United States | 7 | 2025 | 15966 | 0.130 |
Why?
| | Stress, Psychological | 1 | 2025 | 1152 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 887 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1168 | 0.120 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 23 | 0.120 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1313 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2020 | 11679 | 0.100 |
Why?
| | Exercise | 1 | 2026 | 2201 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.100 |
Why?
| | Bridged-Ring Compounds | 2 | 2023 | 31 | 0.100 |
Why?
| | Anesthesia, General | 1 | 2014 | 118 | 0.100 |
Why?
| | Aged | 7 | 2023 | 25913 | 0.090 |
Why?
| | Medicare | 3 | 2023 | 886 | 0.090 |
Why?
| | Birth Rate | 1 | 2012 | 28 | 0.090 |
Why?
| | Micromanipulation | 1 | 2012 | 14 | 0.090 |
Why?
| | Embryo Transfer | 1 | 2012 | 37 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 380 | 0.090 |
Why?
| | Oocytes | 1 | 2012 | 178 | 0.090 |
Why?
| | Odds Ratio | 1 | 2012 | 1075 | 0.080 |
Why?
| | Nanoparticles | 1 | 2015 | 519 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2012 | 476 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2878 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1953 | 0.070 |
Why?
| | Disease Management | 2 | 2024 | 645 | 0.070 |
Why?
| | Child | 1 | 2024 | 22633 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 391 | 0.050 |
Why?
| | Protein Kinases | 1 | 2005 | 315 | 0.050 |
Why?
| | Electrophysiologic Techniques, Cardiac | 2 | 2014 | 84 | 0.050 |
Why?
| | Women's Health | 1 | 2025 | 310 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 5960 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 361 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1053 | 0.040 |
Why?
| | American Heart Association | 1 | 2021 | 350 | 0.040 |
Why?
| | Sex Factors | 1 | 2026 | 2112 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 337 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2020 | 95 | 0.040 |
Why?
| | Pregnancy | 1 | 2012 | 7190 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 965 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2025 | 741 | 0.040 |
Why?
| | Melanoma | 1 | 2005 | 761 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 348 | 0.030 |
Why?
| | Prevalence | 1 | 2025 | 2834 | 0.030 |
Why?
| | Anxiety | 1 | 2025 | 1109 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1462 | 0.030 |
Why?
| | Blood Pressure | 1 | 2024 | 1769 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2025 | 893 | 0.030 |
Why?
| | Middle Aged | 3 | 2014 | 35875 | 0.030 |
Why?
| | Dibenzocycloheptenes | 1 | 2015 | 5 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 125 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1658 | 0.030 |
Why?
| | Biological Availability | 1 | 2015 | 142 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1558 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 242 | 0.030 |
Why?
| | Drug Compounding | 1 | 2015 | 107 | 0.030 |
Why?
| | Philadelphia | 1 | 2014 | 55 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 451 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2015 | 561 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 2014 | 92 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2012 | 17066 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2015 | 594 | 0.020 |
Why?
| | Quality of Life | 1 | 2026 | 3185 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1560 | 0.020 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 142 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 529 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1472 | 0.020 |
Why?
| | Male | 4 | 2026 | 72315 | 0.020 |
Why?
| | Decision Making | 1 | 2018 | 975 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3333 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3671 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 630 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1135 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2115 | 0.020 |
Why?
| | Adult | 1 | 2012 | 40449 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2879 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2117 | 0.020 |
Why?
| | Rats | 1 | 2015 | 5597 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3604 | 0.020 |
Why?
| | Animals | 2 | 2020 | 38058 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 3077 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5408 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 7990 | 0.010 |
Why?
|
|
Kondapalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|